Neurobo Pharmaceuticals Analysis
| NRBODelisted Stock | USD 1.89 0.11 5.50% |
Neurobo Pharmaceuticals is overvalued with Real Value of 1.74 and Hype Value of 1.89. The main objective of Neurobo Pharmaceuticals delisted stock analysis is to determine its intrinsic value, which is an estimate of what Neurobo Pharmaceuticals is worth, separate from its market price. There are two main types of Neurobo Pharmaceuticals' stock analysis: fundamental analysis and technical analysis.
The Neurobo Pharmaceuticals stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Neurobo Pharmaceuticals is usually not traded on Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, National Mourning Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day. Neurobo Stock trading window is adjusted to America/New York timezone.
Neurobo |
Neurobo Stock Analysis Notes
About 65.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 1.57. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Neurobo Pharmaceuticals recorded a loss per share of 4.29. The entity last dividend was issued on the 31st of December 2019. The firm had 1:8 split on the 21st of December 2023. NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company that develops and commercializes multimodal disease-modifying therapies for viral, neuropathic, and neurodegenerative diseases. NeuroBo Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts. Neurobo Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 5 people. To find out more about Neurobo Pharmaceuticals contact HyungHeon Kim at 857 702 9600 or learn more at https://www.neurobopharma.com.Neurobo Pharmaceuticals Investment Alerts
| Neurobo Pharmaceuticals is now traded under the symbol MTVA. Please update your portfolios or report it if you believe this is an error. Report It! | |
| Neurobo Pharmaceuticals is not yet fully synchronised with the market data | |
| Neurobo Pharmaceuticals generated a negative expected return over the last 90 days | |
| Neurobo Pharmaceuticals has high historical volatility and very poor performance | |
| Neurobo Pharmaceuticals may become a speculative penny stock | |
| Neurobo Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 7 K. Net Loss for the year was (12.47 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Neurobo Pharmaceuticals currently holds about 8.85 M in cash with (10.8 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.96, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 65.0% of the company outstanding shares are owned by corporate insiders |
Neurobo Pharmaceuticals Upcoming and Recent Events
Earnings reports are used by Neurobo Pharmaceuticals to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 10th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Neurobo Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 20.33 M.Neurobo Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Neurobo Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Neurobo Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Neurobo Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Neurobo Pharmaceuticals Outstanding Bonds
Neurobo Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Neurobo Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Neurobo bonds can be classified according to their maturity, which is the date when Neurobo Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
Neurobo Pharmaceuticals Predictive Daily Indicators
Neurobo Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Neurobo Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
About Neurobo Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Neurobo Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Neurobo shares will generate the highest return on investment. We also built our delisted stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Delisted Stock such as Neurobo Pharmaceuticals. By using and applying Neurobo Stock analysis, traders can create a robust methodology for identifying Neurobo entry and exit points for their positions.
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company that develops and commercializes multimodal disease-modifying therapies for viral, neuropathic, and neurodegenerative diseases. NeuroBo Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts. Neurobo Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 5 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Neurobo Pharmaceuticals to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Portfolio Diagnostics Now
Portfolio DiagnosticsUse generated alerts and portfolio events aggregator to diagnose current holdings |
| All Next | Launch Module |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Other Consideration for investing in Neurobo Stock
If you are still planning to invest in Neurobo Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Neurobo Pharmaceuticals' history and understand the potential risks before investing.
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |